Atlas Trials

Ovarian High Grade Serous Adenocarcinoma

15 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Ovarian High Grade Serous Adenocarcinoma

RecordFirmDate
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors (NCT04616534)National Cancer Institute (NCI)2021-06-01
National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401)National Cancer Institute (NCI)2020-11-11
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (NCT04092270)National Cancer Institute (NCI)2020-05-07
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927)National Cancer Institute (NCI)2019-12-04
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03587311)National Cancer Institute (NCI)2018-10-12
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707)National Cancer Institute (NCI)2017-06-23
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02627443)National Cancer Institute (NCI)2017-05-16
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02713386)NRG Oncology2016-11-14
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (NCT02345265)National Cancer Institute (NCI)2016-05-23
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707)Mayo Clinic2014-02-24
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648)National Cancer Institute (NCI)2010-04-14

Track Ovarian High Grade Serous Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.